Acute Phosphodiesterase 5 Inhibition Mimics Hemodynamic Effects of B-Type Natriuretic Peptide and Potentiates B-Type Natriuretic Peptide Effects in Failing But Not Normal Canine Heart

Journal of the American College of Cardiology

Volumn 49, Issue 10, 2007, Pages 1079-1088

  Forfia, Paul R ^a   Lee, Myung ^a   Tunin, Richard S ^a   Mahmud, Mobusher ^a   Champion, Hunter C ^a   Kass, David A ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; PHOSPHODIESTERASE V; SILDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; HEART FAILURE; HEART HEMODYNAMICS; HORMONE BLOOD LEVEL; KIDNEY; LUNG; LUNG ARTERY PRESSURE; LUNG CAPILLARY PRESSURE; MEAN ARTERIAL PRESSURE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; VASCULARIZATION;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FEMALE; HEART FAILURE, CONGESTIVE; INFUSIONS, INTRAVENOUS; MALE; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PIPERAZINES; PROBABILITY; PURINES; RANDOM ALLOCATION; REFERENCE VALUES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SULFONES;

EID: 33847364835     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.08.066     Document Type: Article

References (45)

1. Levin E.R., Gardner D.G., and Samson W.K. Natriuretic peptides. N Engl Med 339 (1998) 321-328
2. Hirooka Y., Takeshita A., Imaizumi T., et al. Attenuated forearm vasodilative response to intra-arterial atrial natriuretic peptide in patients with heart failure. Circulation 82 (1990) 147-153
3. Nakamura M., Arakawa N., Yoshida H., et al. Vasodilatory effects of B-type natriuretic peptide are impaired in patients with chronic heart failure. Am Heart J 135 (1998) 414-420
4. Cody R.J., Atlas S.A., Laragh J.H., et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest 78 (1986) 1362-1374
5. Kuhn M. Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A. Circ Res 93 (2003) 700-709
6. Hamet P., Tremblay J., Pang S.C., et al. Cyclic GMP as mediator and biological marker of atrial natriuretic factor. J Hypertens Suppl 4 (1986) S49-S56
7. Nakaoka H., Imataka K., Kitahara Y., et al. Relationship between plasma levels of atrial natriuretic peptide and cyclic guanosine monophosphate in patients with heart diseases. Jpn Circ J 52 (1988) 30-34
8. Tsutamoto T., Kanamori T., Morigami N., et al. Possibility of downregulation of atrial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with chronic severe heart failure. Circulation 87 (1993) 70-75
9. Wilkins M.R., Settle S.L., Stockmann P.T., et al. Maximizing the natriuretic effect of endogenous atriopeptin in a rat model of heart failure. Proc Natl Acad Sci U S A 87 (1990) 6465-6469
10. Charloux A., Piquard F., Doutreleau S., et al. Mechanisms of renal hyporesponsiveness to ANP in heart failure. Eur J Clin Invest 33 (2003) 769-778
11. Ni X.P., Safai M., Gardner D.G., et al. Increased cGMP phosphodiesterase activity mediates renal resistance to ANP in rats with bile duct ligation. Kidney Int 59 (2001) 1264-1273
12. Ni X.P., Safai M., Rishi R., et al. Increased activity of cGMP-specific phosphodiesterase (PDE5) contributes to resistance to atrial natriuretic peptide natriuresis in the pregnant rat. J Am Soc Nephrol 15 (2004) 1254-1260
13. Hanson K.A., Ziegler J.W., Rybalkin S.D., et al. Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. Am J Physiol 275 (1998) L931-L941
14. Black S.M., Sanchez L.S., Mata-Greenwood E., et al. sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 281 (2001) L1051-L1057
15. Katori T., Hoover D.B., Ardell J.L., et al. Calcitonin gene-related peptide in vivo positive inotropy is attributable to regional sympatho-stimulation and is blunted in congestive heart failure. Circ Res 96 (2005) 234-243
16. Rankin J.S., McHale P.A., Arentzen C.E., et al. The three-dimensional dynamic geometry of the left ventricle in the conscious dog. Circ Res 39 (1976) 304-313
17. Supaporn T., Sandberg S.M., Borgeson D.D., et al. Blunted cGMP response to agonists and enhanced glomerular cyclic 3′,5′-nucleotide phosphodiesterase activities in experimental congestive heart failure. Kidney Int 50 (1996) 1718-1725
18. Misra R.P. Isolation of glomeruli from mammalian kidneys by graded sieving. Am J Clin Pathol 58 (1972) 135-139
19. Burnett Jr. J.C., Kao P.C., Hu D.C., et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 231 (1986) 1145-1147
20. Mukoyama M., Nakao K., Hosoda K., et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87 (1991) 1402-1412
21. Stasch J.P., Kazda S., and Neuser D. Different effects of ANP and nitroprusside on cyclic GMP extrusion of isolated aorta. Eur J Pharmacol 174 (1989) 279-282
22. Tsutamoto T., Kanamori T., Wada A., et al. Uncoupling of atrial natriuretic peptide extraction and cyclic guanosine monophosphate production in the pulmonary circulation in patients with severe heart failure. J Am Coll Cardiol 20 (1992) 541-546
23. Margulies K.B., and Burnett Jr. J.C. Inhibition of cyclic GMP phosphodiesterases augments renal responses to atrial natriuretic factor in congestive heart failure. J Card Fail 1 (1994) 71-80
24. Potter L.R., Abbey-Hosch S., and Dickey D.M. Natriuretic peptides, their receptors and cGMP-dependent signaling functions. Endocr Rev 27 (2006) 47-72
25. Hawkridge A.M., Heublein D.M., Bergen III H.R., Cataliotti A., Burnett Jr. J.C., and Muddiman D.C. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A 102 (2005) 17442-17447
26. Corbin J.D., Beasley A., Blount M.A., et al. High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem Biophys Res Commun 334 (2005) 930-938
27. Lainchbury J.G., Burnett Jr. J.C., Meyer D., and Redfield M.M. Effects of natriuretic peptides on load and myocardial function in normal and heart failure dogs. Am J Physiol Heart Circ Physiol 278 (2000) H33-H40
28. Yoshimura M., Yasue H., Morita E., et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 84 (1991) 1581-1588
29. Miller W.L., Hartman K.A., Burritt M.F., Borgeson D.D., Burnett Jr. J.C., and Jaffe A.S. Biomarker responses during and after treatment with nesiritide infusion in patients with decompensated chronic heart failure. Clin Chem 51 (2005) 569-577
30. Fitzgerald R.L., Cremo R., Gardetto N., et al. Effect of nesiritide in combination with standard therapy on serum concentrations of natriuretic peptides in patients admitted for decompensated congestive heart failure. Am Heart J 150 (2005) 471-477
31. Thomas C.J., and Woods R.L. Haemodynamic action of B-type natriuretic peptide substantially outlasts its plasma half-life in conscious dogs. Clin Exp Pharmacol Physiol 30 (2003) 369-375
32. Blonde L., Wehmann R.E., and Steiner A.L. Plasma clearance rates and renal clearance of 3H-labeled cyclic AMP and 3H-labeled cyclic GMP in the dog. J Clin Invest 53 (1974) 163-172
33. Preston I.R., Hill N.S., Gambardella L.S., et al. Synergistic effects of ANP and sildenafil on cGMP levels and amelioration of acute hypoxic pulmonary hypertension. Exp Biol Med (Maywood) 229 (2004) 920-925
34. Zhao L., Mason N.A., Morrell N.W., et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 104 (2001) 424-428
35. Zhao L., Mason N.A., Strange J.W., et al. Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic peptide activity. Circulation 107 (2003) 234-237
36. Turko I.V., Ballard S.A., Francis S.H., and Corbin J.D. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (type 5) by sildenafil and related compounds. Mol Pharmacol 56 (1999) 124-130
37. Abassi Z., Haramati A., Hoffman A., et al. Effect of converting-enzyme inhibition on renal response to ANF in rats with experimental heart failure. Am J Physiol 259 (1990) R84-R89
38. Abassi Z.A., Kelly G., Golomb E., et al. Losartan improves the natriuretic response to ANF in rats with high-output heart failure. J Pharmacol Exp Ther 268 (1994) 224-230
39. Muirhead G.J., Rance D.J., Walker D.K., et al. Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil. Br J Clin Pharmacol 53 Suppl 1 (2002) 13S-20S
40. Leuchte H.H., Holzapfel M., Baumgartner R.A., et al. Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension. Chest 128 (2005) 2368-2374
41. Galie N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 (2005) 2148-2157
42. Klinger J.R., Thaker S., Houtchens J., Preston I.R., Hill N.S., and Farber H.W. Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. Chest 129 (2006) 417-425
43. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287 (2002) 1531-1540
44. Sackner-Bernstein J.D., Kowalski M., Fox M., and Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293 (2005) 1900-1905
45. Sackner-Bernstein J.D., Skopicki H.A., and Aaronson K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111 (2005) 1487-1491